Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis

Hepatology

Volumn 63, Issue 1, 2016, Pages 284-306

  Lok, Anna S F ^a   Mcmahon, Brian J ^b   Brown, Robert S ^c   Wong, John B ^d   Ahmed, Ahmed T ^e   Farah, Wigdan ^e   Almasri, Jehad ^e   Alahdab, Fares ^e   Benkhadra, Khalid ^e   Mouchli, Mohamed A ^e   Singh, Siddharth ^e   Mohamed, Essa A ^e   Abu Dabrh, Abd Moain ^e   Prokop, Larry J ^e   Wang, Zhen ^e   Murad, Mohammad Hassan ^e   Mohammed, Khaled ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Liver Disease and Hepatitis Program   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; CONTROLLED CLINICAL TRIAL (TOPIC); DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; LIVER CIRRHOSIS; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; COMPLICATION; HEPATITIS B, CHRONIC; IMMUNOLOGY;

ADULT; ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 84951792292     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28280     Document Type: Review

References (89)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-2219.
2. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010;202:192-201.
3. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012;56:422-433.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
5. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
6. Murad MH, Montori VM, Ioannidis JP, Jaeschke R, Devereaux PJ, Prasad K, et al. How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature. JAMA 2014;312:171-179.
7. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
8. Anderson MG, Harrison TJ, Alexander G, Zuckerman AJ, Murray-Lyon IM. Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B. Gut 1987;28:619-622.
9. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535-1539.
10. Lin S-M, Yu M-L, Lee C-M, Chien R-N, Sheen IS, Chu C-M, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
11. Truong BX, Seo Y, Kato M, Hamano K, Ninomiya T, Katayama M, et al. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005;16:279-284.
12. Tangkijvanich P, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health 2001;32:452-458.
13. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-313.
14. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
15. Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 2004;11:349-357.
16. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-909.
17. Tong MJ, Blatt LM, Tyson KB, Kao VWC. Death from liver disease and development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a prospective study. Gastroenterol Hepatol (Qué) 2006;2:41-47.
18. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis B. Hepatology 1999;30:257-264.
19. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-270.
20. Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005;25:220-225.
21. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998;82:827-835.
22. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997;26:1338-1342.
23. Krogsgaard K, Thomas HC, Farrell G, Cooksley WGE, Moroni M, Perez V, et al. The long-term effect of treatment with interferon-alpha2a in chronic hepatitis B. J Viral Hepat 1998;5:389-397.
24. Chan HLY, Wang H, Niu J, Chim AML, Sung JJY. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007;12:345-353.
25. Eun LH Jr, Lee SH, Kim TN, Jang BIK, Choi JW, Park YS, et al. The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in HBV-related liver cirrhosis. Hepatology 2007;46:664A-665A.
26. Tong MJ, Hsien C, Song JJ, Kao JH, Sun HE, Hsu L, et al. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci 2009;54:1337-1346.
27. Das K, Das K, Datta S, Pal S, Hembram JR, Dhali GK, et al. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int 2010;30:1033-1042.
28. Cui Y-L, Yan F, Wang Y-B, Song X-Q, Liu L, Lei X-Z, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci 2010;55:2373-2380.
29. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
30. Chan HLY, Tsang SWC, Hui Y, Leung NWY, Chan FKL, Sung JJY. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 2002;9:424-428.
31. Lok ASF, Lai C-L, Leung N, Yao G-B, Cui Z-Y, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.
32. Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004;99:57-63.
33. Liaw Y-F, Sung JJY, Chow WC, Farrell G, Lee C-Z, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
34. Matsumoto A, Tanaka E, Rokuhara A, Omata M, Iino S, Tanikawa K, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005;32:173-184.
35. Ma H, Guo F, Wei L, Sun Y, Wang H. The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis. [in Chinese] Zhonghua Yi Xue Za Zhi 2007;87:1832-1835.
36. Yuen M-F, Seto W-K, Chow DH-F, Tsui K, Wong DK-H, Ngai VW-S, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
37. Sun L-J, Yu J-W, Zhao Y-H, Kang P, Li S-C. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010;25:583-590.
38. Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, et al. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. J Gastroenterol Hepatol 2012;27:1589-1595.
39. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53:118-125.
40. Wong GL-H, Chan HL-Y, Mak CW-H, Lee SK-Y, Ip ZM-Y, Lam AT-H, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537-1547.
41. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
42. Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, et al. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int 2013;7:460-467.
43. Xiao G-M, He K-Y, Jia W-D, Lei C-L, Yang Z. Case-controlled study of entecavir treatment for chronic severe hepatitis B. [in Chinese] Zhonhua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2009;23:56-58.
44. Xu Q-h, Chen L-b, Xu Z, Shu X, Chen N, Cao H, et al. The short-term efficacy of antiviral treatment in patients with acute-on-chronic hepatitis B liver failure. [in Chinese] Zhonhua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2009;23:467-469.
45. Chen J, Han JH, Liu C, Yu RH, Li FZ, Li QF, et al. Short-term entecavir therapy of chronic severe hepatitis B. Hepatobiliary Pancreat Dis Int 2009;8:261-266.
46. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774-780. Erratumin in Hepatology 2011;54:1114.
47. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study. Gastroenterology 2014;147:143-151.
48. Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885-893.
49. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013;58:427-433.
50. Chan HLY, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012;19:732-743.
51. Chang T-T, Gish RG, de Man R, Gadano A, Sollano J, Chao Y-C, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
52. Lai C-L, Shouval D, Lok AS, Chang T-T, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. Erratum in N Engl J Med 2006;354:1863.
53. Lau GKK, Piratvisuth T, Kang XL, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
54. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217.
55. Wang H, Ji YY, Yao GB, Ma XY, Xie Q, Pang HY, et al. Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients. Eur Rev Med Pharmacol Sci 2013;17:636-643.
56. Yang Q, Gong Z-j, Hu D-f. A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period. [in Chinese] Chung Hua Kan Tsang Ping Tsa Chih 2009;17:515-519.
57. Liaw Y-F, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100.
58. Lim Y-S, Han S, Heo N-Y, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-161.
59. Hsu Y-C, Mo L-R, Chang C-Y, Perng D-S, Tseng C-H, Lo G-H, et al. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. Antivir Ther 2012;17:605-612.
60. Wong VW-S, Wong GL-H, Yiu KK-L, Chim AM-L, Chu SH-T, Chan H-Y, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236-242.
61. Liang J, Han T, Xiao S-X. Telbivudine treatment on cirrhosis resulting from chronic hepatitis B. [in Chinese] Chung Hua Kan Tsang Ping Tsa Chih 2009;17:24-27.
62. Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, et al. Entecavir versus lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 2014;60:1127-1134.
63. Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, et al. Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol 2014;20:4745-4752.
64. Tsai WL, Chiang PH, Chan HH, Lin HS, Lai KH, Cheng JS, et al. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother 2014;58:1918-1921.
65. Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, et al. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol 2014;29:568-575.
66. Koklu S, Tuna Y, Gulsen MT, Demir M, Koksal AS, Kockar MC, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013;11:88-94.
67. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014;146:1240-1248.
68. Lu J, Zhang S, Liu Y, Du X, Ren S, Zhang H, et al. Effect of peg-interferon alpha-2a combined with adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. Liver Int 2015;35:1692-1699.
69. Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-870.
70. Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DKH, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation versus continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009;104:1940-1947.
71. Liaw Y-F, Sheen IS, Lee C-M, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
72. Dogan UB, Kara B, Gumurdulu Y, Soylu A, Akin MS. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 2012;23:247-252.
73. Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, et al. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis 2014;28:153-159.
74. Cholongitas E, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, et al. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Ann Gastroenterol 2015;28:109-117.
75. Huang M, Jie Y, Shi H, Li X, Wu Y, Lin G, et al. Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China. Int J Clin Exp Med 2015;8:666-673.
76. Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM, et al. Tenofovir versus entecavir in the treatment of chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother 2015;59:3168-3173.
77. Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, et al. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol 2014;13:1181-1188.
78. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011;55:1235-1240.
79. Tien C, Xu JJ, Chan LS, Chang M, Lim C, Lee S, et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci 2015;60:566-572.
80. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:941-946; e968.
81. Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 2015;62:694-701.
82. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
83. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007;5:921-931.
84. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
85. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
86. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20.
87. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: Immunization of adults. MMWR Recomm Rep 2006;55:1-33; CE31-34.
88. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/. Published March 2015. Accessed on October 23, 2015.
89. Terrault N, Bzowej N, Chang K-M, Hwang J, Jonas M, Murad H. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2015;63:261-283. http://onlinelibrary.wiley.com/doi/10.1002/hep.28156/full.